February 2013, Volume 71, Issue 2, pp 413-418,
Open Access This content is freely available online to anyone, anywhere at any time.
Date: 18 Nov 2012
Combination of three cytotoxic agents in small-cell lung cancer
The established treatment for small-cell lung cancer has been a cisplatin–etoposide combination, as the most effective chemotherapy regimen. Paclitaxel has also been used in combination with cisplatin and etoposide but this has been unacceptable due to the toxicity. This toxicity could be attributed to the three consequent days of treatment with etoposide plus the doses of each of the three drugs. Our objectives were to determine an equal or longer survival and lower toxicity by administering all 3 drugs with low dosage on day one, compared to the established guideline of 3-day administration.
We tested the aforementioned three-drug combination and avoided the toxicity in the majority of patients by administering all 3 drugs on day one. Fifty-one patients (50 evaluable) were recruited from 4 oncology clinics. All patients had histologically or cytologically confirmed small-cell lung cancer with limited and extensive disease in 40 and 60 % of the patients, respectively. The treatment was: cisplatin 75 mg/m2, etoposide 120 mg/m2 (maximum 200 mg), and paclitaxel 135 mg/m2. The agents were administered on day one and repeated every 3 weeks for 6 cycles.
The median survival was 15 months (95 % CI 13.6–16.4) (mean 16 months). Forty-five (90 %) patients achieved a response: 20 (40 %) patients, a complete response and 25 (50 %), a partial response. Adverse reactions included grade 3 and 4 neutropenia in 12 and 2 % of the patients, respectively. Other side effects were of very low toxicity.
The 1-day, three-agent (cisplatin–etoposide–paclitaxel) treatment of small-cell lung cancer is beneficial with respect to response rate and survival, and the toxicity is low and well-tolerated.
Loehrer P, Einhorn L, Greco FA (1988) Cisplatin plus etoposide in small cell lung cancer. Semin Oncol 15:2–8PubMed
Skarlos DV, Samantas E, Kosmidis P et al (1994) Randomised comparison of etoposide-cisplatin vs etoposide-carboplatin and irradiation in small-cell lung cancer. Ann Oncol 5:601–607PubMed
Jett JR, Everson L, Therneau TM et al (1990) Treatment of limited stage small-cell lung cancer with cyclophosphamide, doxorubicin and vincristine with or without etoposide: a randomised trial of the North Central Cancer Treatment Group. J Clin Oncol 18:33–39
Johnson DH, Einhorn LH, Birch R et al (1987) A randomised comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin and vincristine for extensive-stage small cell lung cancer: a Phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 5:1731–1738PubMed
Ettinger DS, Finkelstein DM, Sarma RP et al (1995) Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 13:1430–1435PubMed
Clark PI, Slevin ML, Joel SP et al (1994) A randomised trial of two etoposide schedules in small-cell lung cancer; the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 12:1427–1435PubMed
Roth BJ, Johnson DH, Einhorn LH et al (1992) Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a Phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282–291PubMed
Einhorn LH, Crawford J, Birch R et al (1988) Cisplatin plus etoposide consolidation following cyclopphosphamide, doxorubicin and vincristine in limited small-cell lung cancer. J Clin Oncol 6:451–456PubMed
Loeher PJ, Ansari R, Gonin R et al (1995) Cisplatin plus etoposide with or without ifosfamide in extensive small cell lung cancer: a Hoosier Oncology Group Study. J Clin Oncol 13:2594–2599
Bleehen NM, Girling DJ, Machin D et al (1993) A randomised trial of three to six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC) I: survival and prognostic factors. Medical Research Council Lung Cancer Working Party. Br J Cancer 68(6):1150–1156PubMedCrossRef
Giaccone G, Dalesio O, McVie GJ et al (1993) Maintenance chemotherapy in small-cell lung cancer: long term results of a randomised trial. European Organisation for Research and Treatment of Cancer, Lung Cancer Cooperative Group. J Clin Oncol 11(7):1230–1240PubMed
Sculier JP, Paesmans M, Bureau G et al (1996) Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 14(8):2337–2344PubMed
Thatcher N, Girling DJ, Hopwood P et al (2000) Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity or chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council. Multicenter randomized trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 18(2):395–404PubMed
Pujol JL, Douillard JY, Rivière A et al (1997) Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor 1997 in extensive-stage small-cell lung cancer: a multicenter randomized Phase III study. J Clin Oncol 15(5):2082–2089PubMed
Bunn PA, Kelly K (1997) A Phase I study of cisplatin, etoposide and paclitaxel in small-cell lung cancer. Semin Oncol 24(suppl. 12):144–148
Dimitroulis J, Rapti A, Stathopoulos GP et al (2008) Comparison of cisplatin-paclitaxel-etoposide combination versus cisplatin-etoposide in patients with small-cell lung cancer. A Phase III study. Oncol Rep 20:879–884PubMed
- Combination of three cytotoxic agents in small-cell lung cancer
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Cancer Chemotherapy and Pharmacology
Volume 71, Issue 2 , pp 413-418
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Small-cell lung cancer
- Three-drug combination treatment
- Three drugs small-cell lung cancer
- Industry Sectors
- Author Affiliations
- 1. First Oncology Clinic, Errikos Dunant Hospital, Semitelou 2A, 115 28, Athens, Greece
- 2. 6th Pulmonary Clinic, Hospital for Thoracic Diseases, Athens, Greece
- 3. Oncology Clinic, Anticancer Hospital, Piraeus, Greece
- 4. Oncology Clinic, Anticancer Hospital, Thessaloníki, Greece